Novo Nordisk Expands AI Use With OpenAI Partnership

Novo Nordisk is intensifying its use of artificial intelligence by partnering with OpenAI, the parent company of ChatGPT. This collaboration is designed to accelerate drug discovery processes and enhance operational efficiency across the pharmaceutical giant's business. The agreement outlines an expansion of AI integration into Novo Nordisk's operations, with a target completion date of 2026. This strategic move underscores the growing importance of AI in the healthcare and pharmaceutical sectors for innovation and competitive advantage.